SVB Wealth’s Cabaletta Bio CABA Stock Holding History

SVB Wealth’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-231	Closed	-$320	–	701
2025 Q1	$320	Buy	+231	New	+$492	﹤0.01%	1439

Other funds holding CABA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

SVB Wealth's CABA Position: Q2 2025 in Review

SVB Wealth sold out of Cabaletta Bio (CABA) in Q2 2025, closing a stake of 231 shares — an estimated $320 sold.

SVB Wealth first reported a position in CABA in Q1 2025 and held it in 1 quarter. The position peaked at $320 in Q1 2025. 86 funds tracked by Wall St. Rank hold CABA as of Q2 2025.

SVB Wealth reported no remaining Cabaletta Bio position as of Q2 2025 after selling out during the quarter.
SVB Wealth sold 231 Cabaletta Bio shares in Q2 2025, an estimated $320.
SVB Wealth first reported a position in Cabaletta Bio in Q1 2025 and held it in 1 quarter.
SVB Wealth's Cabaletta Bio position peaked at $320 in Q1 2025.
86 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2025.

Based on SVB Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.